| |
| |
|
| Insider
Information: |
Papadopoulos Stelios |
| Relationship: |
Director, 10% Owner |
| City: |
Gaithersburg |
| State: |
MD |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
4,592,750 |
|
|
Indirect Shares
|
4,643,486 |
|
|
| Direct
Value |
$32,049,392 |
|
|
|
Indirect Value
|
$32,648,514 |
|
|
| Total
Shares |
9,236,236 |
|
|
| Total
Value |
$64,697,906 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -56.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Genvec Inc |
GNVC |
Director |
2003-08-21 |
305,840 |
|
0 |
Premium* |
|
|
Anadys Pharmaceuticals Inc |
ANDS |
Director |
2007-09-14 |
814,206 |
2004-03-25 |
1,995,374 |
Premium* |
|
|
Sgx Pharmaceuticals, Inc. |
SGXP |
Director |
2006-02-06 |
35,930 |
2006-02-06 |
0 |
Premium* |
|
|
Biogen Idec Inc |
BIIB |
Director |
2022-06-15 |
10,095 |
2022-06-15 |
28,206 |
Premium* |
|
|
Exelixis Inc |
EXEL |
Director |
2024-05-20 |
1,260,578 |
2017-09-22 |
0 |
Premium* |
|
|
Bg Medicine, Inc. |
BGMD |
Director |
2013-01-30 |
1,187,713 |
2011-02-09 |
0 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
|
2024-03-14 |
978,388 |
2014-12-12 |
0 |
Premium* |
|
|
Eucrates Biomedical Acquisition ... |
EUCR |
Director, 10% Owner |
|
0 |
2020-11-24 |
2,619,906 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
85 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2018-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,450 |
3,190 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2018-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
20,910 |
168,672 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2018-11-15 |
4 |
B |
$1.33 |
$265,080 |
D/D |
200,000 |
368,672 |
2.39 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2018-11-16 |
4 |
B |
$1.38 |
$415,470 |
D/D |
300,000 |
668,672 |
2.39 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2018-12-26 |
4 |
B |
$0.95 |
$85,878 |
D/D |
90,000 |
758,672 |
2.39 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2018-12-27 |
4 |
B |
$1.04 |
$27,460 |
D/D |
26,401 |
785,073 |
2.39 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2018-12-28 |
4 |
B |
$1.09 |
$54,570 |
D/D |
50,000 |
835,073 |
2.39 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2019-02-21 |
4 |
OE |
$4.16 |
$115,350 |
D/D |
26,250 |
1,068,501 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2019-02-21 |
4 |
S |
$21.25 |
$557,813 |
D/D |
(26,250) |
1,042,251 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2019-05-07 |
4/A |
A |
$1.08 |
$400,000 |
D/D |
370,370 |
1,189,872 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2019-05-07 |
4 |
B |
$1.08 |
$400,000 |
D/D |
370,370 |
1,189,872 |
2.39 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,317 |
1,052,568 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2019-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,905 |
5,095 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
846,320 |
2,039,521 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-05-08 |
4 |
S |
$25.84 |
$1,162,800 |
D/D |
(45,000) |
1,052,568 |
0 |
% |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-05-08 |
4 |
OE |
$4.58 |
$226,200 |
D/D |
45,000 |
1,097,568 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-05-13 |
4 |
OE |
$5.82 |
$703,004 |
D/D |
120,791 |
1,173,359 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,538 |
1,188,897 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,470 |
6,565 |
0 |
- |
|
| EUCR |
Eucrates Biomedical Acqui... |
Director |
– • • |
2020-10-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,875,000 |
|
- |
|
| EUCR |
Eucrates Biomedical Acqui... |
Director |
– • • |
2020-11-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(255,094) |
2,619,906 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.63 |
$500,002 |
D/D |
793,528 |
1,986,729 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2020-12-04 |
4/A |
A |
$0.63 |
$500,002 |
D/D |
793,528 |
2,839,707 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2021-05-11 |
4 |
OE |
$3.13 |
$512,400 |
D/D |
120,000 |
1,293,600 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2021-05-11 |
4 |
S |
$24.95 |
$518,794 |
D/D |
(20,770) |
1,288,127 |
0 |
% |
|
85 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
